Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

Patients with multiple myeloma (MM) who experience deep remissions, including minimal residual disease (MRD) negativity, have better clinical outcomes compared to those do not. We aimed to describe the effect of testing for MRD negativity in a cohort of MM patients outside of a clinical trial. For most patients, MRD negativity supports improved clinical outcomes. However, in our cohort of patients with high-risk MM, MRD negativity does not seem to affect the overall poor prognosis.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 14, 2020 Category: Hematology Authors: Chutima Kunacheewa, Hans C. Lee, Krina Patel, Sheeba Thomas, Behrang Amini, Samer Srour, Qaiser Bashir, Yago Nieto, Muzzaffar H. Qazilbash, Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch Tags: Original Study Source Type: research